FreeStyle Libre, the first sensor-based glucose monitoring system listed in any Canadian provincial health plan, gained public reimbursement in Ontario and Quebec.

Abbott enters new collaborations with Sanofi, Omada Health and Tandem Diabetes Care to provide people with diabetes a connected device experience.

MitraClip sales increased 30.4% on a GAAP basis. MitraClip G4 — Now approved in the U.S., our next-generation device for mitral valve repair includes new clip sizes and an enhanced leaflet grasping feature.

Adjusted diluted EPS midpoint reflects double-digit growth.

COAPT® Trial data show MitraClip® is cost-effective, increases life expectancy and improves quality of life.

MitraClip® G4 — Now approved in the U.S., our next-generation device for mitral valve repair includes new clip sizes and an enhanced leaflet grasping feature.

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Strong adoption of Alinity family of advanced diagnostic testing technologies due to increased speed and efficiency in laboratories.

Alinity® — Our most advanced system for screening blood and plasma is now approved in the U.S. to help keep the blood supply safe.

A major component of Abbott’s family of advanced diagnostic testing technologies. Real-time speed and efficiency in lab operations.

Alinity™ — Our most advanced system for screening blood and plasma is now approved in the U.S. to help keep the blood supply safe.

MitraClip® — Now approved in the U.S., our next-generation device for mitral valve repair includes new clip sizes and an enhanced leaflet grasping feature.

COAPT® — Data show MitraClip® is cost-effective, increases life expectancy and improves quality of life.

MitraClip® G4 — Now approved in the U.S., our next-generation device for mitral valve repair includes new clip sizes and an enhanced leaflet grasping feature.

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Strong adoption of Alinity family of advanced diagnostic testing technologies due to increased speed and efficiency in laboratories.

Alinity® — Our most advanced system for screening blood and plasma is now approved in the U.S. to help keep the blood supply safe.

A major component of Abbott’s family of advanced diagnostic testing technologies. Real-time speed and efficiency in lab operations.

Alinity™ — Our most advanced system for screening blood and plasma is now approved in the U.S. to help keep the blood supply safe.

MitraClip® — Now approved in the U.S., our next-generation device for mitral valve repair includes new clip sizes and an enhanced leaflet grasping feature.

COAPT® — Data show MitraClip® is cost-effective, increases life expectancy and improves quality of life.

MitraClip® G4 — Now approved in the U.S., our next-generation device for mitral valve repair includes new clip sizes and an enhanced leaflet grasping feature.

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Strong adoption of Alinity family of advanced diagnostic testing technologies due to increased speed and efficiency in laboratories.

Alinity® — Our most advanced system for screening blood and plasma is now approved in the U.S. to help keep the blood supply safe.

A major component of Abbott’s family of advanced diagnostic testing technologies. Real-time speed and efficiency in lab operations.

Alinity™ — Our most advanced system for screening blood and plasma is now approved in the U.S. to help keep the blood supply safe.

MitraClip® — Now approved in the U.S., our next-generation device for mitral valve repair includes new clip sizes and an enhanced leaflet grasping feature.

COAPT® — Data show MitraClip® is cost-effective, increases life expectancy and improves quality of life.

MitraClip® G4 — Now approved in the U.S., our next-generation device for mitral valve repair includes new clip sizes and an enhanced leaflet grasping feature.

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Strong adoption of Alinity family of advanced diagnostic testing technologies due to increased speed and efficiency in laboratories.

Alinity® — Our most advanced system for screening blood and plasma is now approved in the U.S. to help keep the blood supply safe.

A major component of Abbott’s family of advanced diagnostic testing technologies. Real-time speed and efficiency in lab operations.

Alinity™ — Our most advanced system for screening blood and plasma is now approved in the U.S. to help keep the blood supply safe.

MitraClip® — Now approved in the U.S., our next-generation device for mitral valve repair includes new clip sizes and an enhanced leaflet grasping feature.

COAPT® — Data show MitraClip® is cost-effective, increases life expectancy and improves quality of life.

MitraClip® G4 — Now approved in the U.S., our next-generation device for mitral valve repair includes new clip sizes and an enhanced leaflet grasping feature.

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Strong adoption of Alinity family of advanced diagnostic testing technologies due to increased speed and efficiency in laboratories.

Alinity® — Our most advanced system for screening blood and plasma is now approved in the U.S. to help keep the blood supply safe.

A major component of Abbott’s family of advanced diagnostic testing technologies. Real-time speed and efficiency in lab operations.

Alinity™ — Our most advanced system for screening blood and plasma is now approved in the U.S. to help keep the blood supply safe.

MitraClip® — Now approved in the U.S., our next-generation device for mitral valve repair includes new clip sizes and an enhanced leaflet grasping feature.

COAPT® — Data show MitraClip® is cost-effective, increases life expectancy and improves quality of life.

MitraClip® G4 — Now approved in the U.S., our next-generation device for mitral valve repair includes new clip sizes and an enhanced leaflet grasping feature.

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Strong adoption of Alinity family of advanced diagnostic testing technologies due to increased speed and efficiency in laboratories.

Alinity® — Our most advanced system for screening blood and plasma is now approved in the U.S. to help keep the blood supply safe.

A major component of Abbott’s family of advanced diagnostic testing technologies. Real-time speed and efficiency in lab operations.

Alinity™ — Our most advanced system for screening blood and plasma is now approved in the U.S. to help keep the blood supply safe.

MitraClip® — Now approved in the U.S., our next-generation device for mitral valve repair includes new clip sizes and an enhanced leaflet grasping feature.